Although we agree that greater investments are needed in the clinical
development of these therapies, we disagree with the authors» suggestion that, relative to embryonic stem cells, adult stem cells provide a superior vehicle for cell - based therapies because they lack
tumorigenic activity, can be prepared by methods approved by the Food and Drug Administration (FDA), and have been free of ethical controversy.